Our Executive Clinical Pharmacy team discusses the Immune Globulin (IG) shortage affecting hospitals, infusion centers, specialty pharmacies, and payers across the United States.
Topics included in this episode:
-
Severity
-
Causes of the shortage
-
Manufacturer comments
-
Treatment options - clinical efficacy and differentiation
-
Patient prioritization tactics
-
Switching and substitution
-
Payer impacts
-
Effects on the pharmaceutical market
-
Potential for resolution
IPD'S DRUG & CLINICAL REVIEW:
IMMUNE GLOBULIN SHORTAGE FALL 2019
“Well, it's definitely a serious issue that have left many asking, ‘what has caused this shortage?’”
“Recently there has been an immune globulin shortage due to many reasons, including higher rates of diagnosis of conditions that immune globulin treats. But yes, you're right. It's basically economics 101; demand is greater than supply. We have an increased utilization of immune globulin and supply that just can't keep up. The shortage has resulted in immune globulin having to be prioritized to those patients in most need.”